Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The launch of Dr. Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), is an important addition to the Pain/ Analgesics portfolio of OTC products, and represents the continued commitment to the Private Label OTC space.
Product Name : Diclofenac Sodium-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2020
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Voltaren (Diclofenac Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain.
Product Name : Voltaren
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DARE-PDM1 (diclofenac) is a vaginal hydrogel which inhibits Cox-1 and Cox-2. It is being evaluated in phase 1 clinical trials for the treatment of primary dysmenorrhea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DARE-PDM1 is a novel delivery of the diclofenac sodium, a NSAID drug which inhibits COX-1 and COX-2 responsible for producing PGs which contributes in inflammation and pain signalling. It uses Daré’s proprietary hydrogel technology targeted at treatin...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Because there are currently no FDA-approved vaginal diclofenac treatment options for primary dysmenorrhea, DARE-PDM1 has the potential to be a first-in-category product.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Authorized Generic Version of PENNSAID® 2% w/w in the United States
Details : Diclofenac topical solution is used to treat pain and swelling caused by osteoarthritis of the knees. Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID®) had estimated annual sales of USD 509 million in the U.S.
Product Name : Diclofenac Sodium-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2022
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wounds and Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 24, 2020
Lead Product(s) : Diclofenac Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
